Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Rapid Detection of Anti-SARS-CoV-2 Antibodies With a Screen-Printed Electrode Modified With a Spike Glycoprotein Epitope

Version 1 : Received: 26 March 2022 / Approved: 29 March 2022 / Online: 29 March 2022 (08:39:31 CEST)

How to cite: Ameku, W.; Provance, D.; Morel, C.; De-Simone, S. Rapid Detection of Anti-SARS-CoV-2 Antibodies With a Screen-Printed Electrode Modified With a Spike Glycoprotein Epitope. Preprints 2022, 2022030375 (doi: 10.20944/preprints202203.0375.v1). Ameku, W.; Provance, D.; Morel, C.; De-Simone, S. Rapid Detection of Anti-SARS-CoV-2 Antibodies With a Screen-Printed Electrode Modified With a Spike Glycoprotein Epitope. Preprints 2022, 2022030375 (doi: 10.20944/preprints202203.0375.v1).

Abstract

The coronavirus disease of 2019, COVID-19, is caused by an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was recognized in late 2019 and has since spread worldwide leading to a pandemic with unprecedented health and financial consequences. There remains an enormous demand for new diagnostic methods that can deliver fast, low-cost, and easy-to-use confirmation of a SARS-CoV-2 infection. We have developed an affordable electrochemical biosensor for the rapid detection of serological immunoglobulin (Ig) G antibody in sera against the Spike protein. Materials and Methods: A previously identified linear B-cell epitope (EP) specific to SARS-CoV-2 spike glycoprotein and recognized by IgG in patient sera was selected for the target molecule. After synthesis, the EP was immobilized onto the surface of the working electrode of a commercially available screen-printed electrode (SPE). The capture of SARS-CoV-2 specific IgGs allowed the formation of an immunocomples that was measured by square wave voltammetry from its generation of hydroquinone (HQ). Results: An evaluation of the performance of the EP-based biosensor presented a selectivity and specificity for COVID-19 of 93% and 100%, respectively. No cross-reaction was observed to antibodies against other diseases that included Chagas disease, Chikungunya, Leishmaniosis, and Dengue. Differentiation of infected and non-infected individuals was possible even at high dilution factor that decreased the required sample volumes to a few microliters. Conclusion: The final device proved suitable for diagnosing COVID-19 assaying actual serum samples and the results displayed good agreement with the molecular biology diagnoses. The flexibility to conjugate other EPs to SPEs suggests that this technology could be rapidly adapted to diagnose new variants of SARS-CoV-2 or other pathogens.

Keywords

SARS-CoV-2; COVID-19; spike glycoprotein; epitope; electrochemical biosensor; point of care; immunological diagnostic

Subject

LIFE SCIENCES, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.